The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

Hard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has agreed a deal to ramp up manufacturing – and claim the first doses to be made.

Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause havoc ...

Sanofi and Regeneron’s blockbuster biologic Dupixent ... Dupixent, a fully human monoclonal antibody, inhibits the signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...